LinqMed Inc. is a leading Japanese biotech and radiopharmaceutical startup that develops innovative “visible” anti-cancer treatments. Utilizing a theranostic drug platform based on the copper radioisotope Copper-64 (⁶⁴Cu), the company creates advanced therapies that allow clinicians to simultaneously diagnose and treat refractory cancers (such as malignant brain tumors) using real-time imaging.